Literature DB >> 16518308

Tubedown-1 (Tbdn-1) suppression in oxygen-induced retinopathy and in retinopathy of prematurity.

Robert L Gendron1, William V Good, Ewa Miskiewicz, Stephanie Tucker, Dale L Phelps, Helene Paradis.   

Abstract

PURPOSE: Identification of unique proteins involved in retinopathy of prematurity (ROP) may facilitate new and more effective diagnostic tools and molecular-based treatments for ROP. Tubedown-1 (Tbdn-1), a novel homeostatic protein which copurifies with an acetyltransferase activity, is expressed in normal retinal endothelium and is specifically suppressed in retinal endothelial cells from patients with proliferative diabetic retinopathy. Furthermore, recent in vivo knockdown studies in mice have revealed that Tbdn-1 is important for retinal blood vessel homeostasis and for preventing retinal neovascularization in adults. The purpose of the present study was to determine if the expression pattern of Tbdn-1 is altered during oxygen-induced retinal neovascularization in mice and in a specimen of stage 3 human ROP.
METHODS: Specimens of oxygen-induced retinal neovascularization in mice, and a single specimen of active stage 3 ROP were studied by immunohistochemistry and digital image analysis using antibodies raised against Tbdn-1 and other blood vessel markers.
RESULTS: The pattern of Tbdn-1 expression during the course of oxygen-induced retinal neovascularization in mice suggests a regulating role in neonatal retinopathy. Retinal lesions from oxygen-induced retinal neovascularization in mice display suppression of retinal endothelial Tbdn-1 protein expression in conjunction with an increase in expression of proliferating cell nuclear antigen (a marker of proliferation) and alpha smooth muscle actin (a marker of myofibroblastic cells). Abnormal blood vessels within vitreoretinal neovascular lesions in a human specimen of active stage 3 ROP did not show Tbdn-1 protein expression.
CONCLUSIONS: These results suggest that the loss of retinal endothelial Tbdn-1 expression may be a contributing factor in retinal blood vessel proliferation in ROP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518308

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  7 in total

1.  Adenosine A1 Receptors Selectively Modulate Oxygen-Induced Retinopathy at the Hyperoxic and Hypoxic Phases by Distinct Cellular Mechanisms.

Authors:  Shuya Zhang; Haiyan Li; Bo Li; Dingjuan Zhong; Xuejiao Gu; Lingyun Tang; Yanyan Wang; Cun Wang; Rong Zhou; Yan Li; Yan He; Mozi Chen; Yuqing Huo; Xiao-Ling Liu; Jiang-Fan Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

Review 2.  The biological functions of Naa10 - From amino-terminal acetylation to human disease.

Authors:  Max J Dörfel; Gholson J Lyon
Journal:  Gene       Date:  2015-05-16       Impact factor: 3.688

3.  Composition and biological significance of the human Nalpha-terminal acetyltransferases.

Authors:  Kristian K Starheim; Darina Gromyko; Rolf Velde; Jan Erik Varhaug; Thomas Arnesen
Journal:  BMC Proc       Date:  2009-08-04

Review 4.  Evidence for a critical role of panretinal pathophysiology in experimental ROP.

Authors:  Bruce A Berkowitz; Robin Roberts
Journal:  Doc Ophthalmol       Date:  2009-06-09       Impact factor: 2.379

5.  Osmotic pressure-adaptive responses in the eye tissues of rainbow smelt (Osmerus mordax).

Authors:  Robert L Gendron; Elizabeth Armstrong; Hélène Paradis; Lacey Haines; Mariève Desjardins; Connie E Short; Kathy A Clow; William R Driedzic
Journal:  Mol Vis       Date:  2011-10-05       Impact factor: 2.367

6.  Tubedown regulation of retinal endothelial permeability signaling pathways.

Authors:  Nhu Ho; Robert L Gendron; Kindra Grozinger; Maria A Whelan; Emily Anne Hicks; Bimal Tennakoon; Danielle Gardiner; William V Good; Hélène Paradis
Journal:  Biol Open       Date:  2015-07-03       Impact factor: 2.422

7.  CD10+ Cells and IgM in Pathogen Response in Lumpfish (Cyclopterus lumpus) Eye Tissues.

Authors:  Robert L Gendron; Hélène Paradis; Raahyma Ahmad; Kenneth Kao; Danny Boyce; William V Good; Surendra Kumar; Ignacio Vasquez; Trung Cao; Ahmed Hossain; Setu Chakraborty; Katherinne Valderrama; Javier Santander
Journal:  Front Immunol       Date:  2020-11-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.